Alison Birtle
Lancashire Teaching Hospitals NHS Foundation Trust(GB)University of Central Lancashire(GB)University of Lancashire(GB)University of Manchester(GB)Rosemere Cancer Foundation(GB)Royal Preston Hospital(GB)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Bladder and Urothelial Cancer Treatments, Radiopharmaceutical Chemistry and Applications, Urinary and Genital Oncology Studies, Prostate Cancer Diagnosis and Treatment
Most-Cited Works
- → Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial(2015)1,944 cited
- → Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy(2017)1,740 cited
- → Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial(2016)1,288 cited
- → Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial(2018)1,234 cited
- → Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial(2020)514 cited
- → European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update